Microvascular dysfunction and heart failure with preserved ejection fraction

Heart Failure

Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction

J Am Heart Assoc

Okada M, Tanaka N, Iwakura K, Onishi T, Seo M, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Tamaki S, Yasumura Y, Yamada T, Sakamoto D, Hikoso S, Okada K, Nakatani D, Sotomi Y, Sakata Y, OCVC‐Heart Failure Investigators

doi: 10.1161/JAHA.124.040646

Heart Failure

Prognostic utility of advanced lung cancer inflammation index in heart failure with preserved ejection fraction

ESC Heart Fail

Sakamoto D, Matsuoka Y, Seo M, Yamada T, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Tamaki S, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Yasumura Y, Hikoso S, Sotomi Y, Sakata Y, OCVC‐Heart Failure Investigators

doi: 10.1002/ehf2.15313

Heart Failure

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

JACC Heart Fail

Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O

doi: 10.1016/j.jchf.2025.102585

Heart Failure

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials

JACC Heart Fail

Lassen MCH, Ostrominski JW, Claggett BL, Neuen BL, Beldhuis IE, Butt J, Biering-Sørensen T, Desai AS, Lewis EF, Jhund PS, Mc Causland F, Anand IS, Pfeffer MA, Pitt B, Zannad F, Zile MR, McMurray JJV, Solomon SD, Vaduganathan M

doi: 10.1016/j.jchf.2025.03.042

Heart Failure

Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial

Eur Heart J

Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Litwin S, Zile M, Desai AS, Jhund PS, Butt JH, Lam CSP, Martinez F, Van Veldhuisen DJ, Zannad F, Rouleau J, Lefkowitz M, McMurray JJV, Solomon SD, Packer M

doi: 10.1093/eurheartj/ehaf057

Heart Failure

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Circ Heart Fail

Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1161/CIRCHEARTFAILURE.125.013201

Heart Failure

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

JACC Heart Fail

Harrington J, Giczewska A, Rao VN, Fudim M, Peters AE, Chrischilles E, Jones WS, May H, Steinberg BA, VanWormer J, Cyr DD, Felker GM

doi: 10.1016/j.jchf.2025.102768

Heart Failure

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Eur J Heart Fail

Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ

doi: 10.1002/ejhf.70006

Heart Failure

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JACC Heart Fail

Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD

doi: 10.1016/j.jchf.2025.102590

Related content

Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction

Prognostic utility of advanced lung cancer inflammation index in heart failure with preserved ejection fraction

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials

Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction